Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Phase II Study to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults With Moderate to Severe Autoimmune Bullous Disease

Next Previous
Trial Profile

An Open-label, Phase II Study to Evaluate the Efficacy and Safety of CM336 (BCMA/CD3 Bispecific Antibody) in Adults With Moderate to Severe Autoimmune Bullous Disease

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gamgertamig (Primary)
  • Indications Bullous erythroderma ichthyosiforme; Bullous pemphigoid
  • Focus Therapeutic Use

Most Recent Events

  • 06 Apr 2026 Planned End Date changed from 1 Jan 2027 to 1 Jan 2028.
  • 06 Apr 2026 Planned primary completion date changed from 1 Jan 2026 to 1 Jan 2027.
  • 02 Apr 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top